Integrative Bioinformatics‐Driven Discovery of the Novel Chimeric Antigen Receptor (CAR)‐T Cell Targets Erb‐B2 Receptor Tyrosine Kinase 3 (ErbB3) and Solute Carrier Family 1 Member 5 (SLC1A5) in Melanoma

Chimeric antigen receptor (CAR) T cell therapy has shown limited success in solid tumors, mainly because of the scarcity of tumor‐specific surface antigens. To address this challenge, we developed an integrated computational and experimental pipeline for antigen discovery and applied it to melanoma. Our bioinformatics strategy introduced a novel quantitative metric, the restrictiveness ratio , to identify antigens highly expressed in tumors but minimally present in healthy tissues. Using RNA‐sequencing data from patient samples, we compared candidate targets with the established melanoma antigen chondroitin sulphate proteoglycan 4 (CSPG4) and validated their expression on melanoma cell lines. CARs were engineered against selected antigens, CAR‐T cells were generated by RNA electroporation, and expression was confirmed. Functional validation included T cell activation, cytokine secretion, and cytotoxicity assays. RNA‐seq analysis of cutaneous and uveal melanoma identified 90 and 84 candidate genes, respectively, encoding transmembrane proteins with tumor expression above 10 TPM (transcripts per million). Fifty‐six genes displayed higher restrictiveness ratios than CSPG4. Following manual curation and scFv (single‐chain variable fragment) availability assessment, five candidates were prioritized. CARs targeting ErbB3 and SLC1A5 induced strong antigen‐specific T cell activation and cytotoxicity comparable to CSPG4‐CARs. These findings identify ErbB3 and SLC1A5 as promising CAR‐T targets and establish an integrative bioinformatics‐driven framework for extending CAR‐T therapy to solid tumors.

Authors

Institutions

Publication Details

Journal
MedComm
Published
2026-11-18
DOI
https://doi.org/10.1002/mco2.71154
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrative Bioinformatics‐Driven Discovery of the Novel Chimeric Antigen Receptor (CAR)‐T Cell Targets Erb‐B2 Receptor Tyrosine Kinase 3 (ErbB3) and Solute Carrier Family 1 Member 5 (SLC1A5) in Melanoma

Martine Johanna Jager, Elias A. T. Koch, Esther Güse, Niels Schaft et al.
MedComm
CAR-T cell therapy research
article

Integrative Bioinformatics‐Driven Discovery of the Novel Chimeric Antigen Receptor (CAR)‐T Cell Targets Erb‐B2 Receptor Tyrosine Kinase 3 (ErbB3) and Solute Carrier Family 1 Member 5 (SLC1A5) in Melanoma

Martine Johanna Jager, Elias A. T. Koch, Esther Güse, Niels Schaft, Markus Biburger, Beatrice Schuler‐Thurner, Carola Berking, Julio Vera, Jan Dörrie, Christopher Lischer, Niklas Feuchter, Kilian F. Juraschek, Maartje M. C. Hof
article en

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown limited success in solid tumors, mainly because of the scarcity of tumor‐specific surface antigens. To address this challenge, we developed an integrated computational and experimental pipeline for antigen discovery and applied it to melanoma. Our bioinformatics strategy introduced a novel quantitative metric, the restrictiveness ratio , to identify antigens highly expressed in tumors but minimally present in healthy tissues. Using RNA‐sequencing data from patient samples, we compared candidate targets with the established melanoma antigen chondroitin sulphate proteoglycan 4 (CSPG4) and validated their expression on melanoma cell lines. CARs were engineered against selected antigens, CAR‐T cells were generated by RNA electroporation, and expression was confirmed. Functional validation included T cell activation, cytokine secretion, and cytotoxicity assays. RNA‐seq analysis of cutaneous and uveal melanoma identified 90 and 84 candidate genes, respectively, encoding transmembrane proteins with tumor expression above 10 TPM (transcripts per million). Fifty‐six genes displayed higher restrictiveness ratios than CSPG4. Following manual curation and scFv (single‐chain variable fragment) availability assessment, five candidates were prioritized. CARs targeting ErbB3 and SLC1A5 induced strong antigen‐specific T cell activation and cytotoxicity comparable to CSPG4‐CARs. These findings identify ErbB3 and SLC1A5 as promising CAR‐T targets and establish an integrative bioinformatics‐driven framework for extending CAR‐T therapy to solid tumors.

MedCommVol. 7(12)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Leiden University Medical Center (NL), Universitätsklinikum Erlangen (DE), Comprehensive Cancer Center Erlangen (DE)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon